Imatinib is used to treat CML, Ph+ ALL, GISTs with c-KIT mutations, and DFSP. It is also approved for MDS/MPD, aggressive systemic mastocytosis, and hypereosinophilic syndrome or chronic eosinophilic leukemia with specific mutations. By blocking key tyrosine kinases that drive abnormal cell growth, it helps control disease progression and improve outcomes.

Imatinib works by blocking tyrosine kinases especially the abnormal BCR-ABL protein that drives CML and some ALL cases. It also inhibits c-KIT and PDGFR, which are involved in GISTs and other cancers. By stopping these proteins from signaling, Imatinib slows or prevents cancer cell growth.

Imatinib is administered orally in the form of tablets, which are taken by mouth with a large glass of water and preferably with food to reduce the risk of stomach upset. The dosage and frequency depend on the type of cancer being treated, the patient's age, weight, and overall health. It is important that the tablets are swallowed whole and not crushed or chewed unless advised by a healthcare provider.

Imatinib may cause a range of side effects, which can vary in severity from person to person. Common side effects include nausea, vomiting, diarrhea, abdominal pain, and fatigue. Some people may experience swelling, especially around the eyes and ankles, as well as muscle cramps, rash, or headache. More serious but less common side effects include liver problems, low blood cell counts (leading to increased risk of infection, bleeding, or anemia), and fluid retention in the lungs or heart. Regular monitoring through blood tests and medical check-ups is important to detect and manage any adverse effects early during treatment with Imatinib.

Imatinib is contraindicated in patients with known hypersensitivity to the drug. It should be used cautiously in those with liver, kidney, or heart problems, or a history of fluid retention. The drug can lower blood cell counts, so regular monitoring is needed. Use during pregnancy or breastfeeding is not recommended, and effective contraception is advised. Medication interactions are possible, so a full review of other drugs is important before starting therapy.

Imatinib is a major breakthrough in cancer therapy, offering effective, targeted treatment for CML, GISTs, and other cancers by blocking abnormal tyrosine kinases. It helps many patients achieve long-term remission and is generally well-tolerated, though regular monitoring is important due to potential side effects.

Imatinib blocks certain proteins (called tyrosine kinases) like BCR-ABL, c-KIT, and PDGFR. These proteins can cause cancer cells to grow uncontrollably. By blocking them, Imatinib helps stop cancer cell growth.

Some patients develop resistance to Imatinib. This can happen because of changes (mutations) in the cancer cells, an increase in the number of target proteins, or because the cancer finds a different way to grow. In such cases, other medicines may be needed.

Some CML patients who have had very good results (deep response) for over 2 years may be able to stop Imatinib under close medical supervision. However, the disease might return, so regular check-ups are needed.

Yes. Imatinib can change how the liver processes other drugs. This means it can make some medicines stronger or weaker. Always tell your doctor about other medications you're taking.

These proteins also help some other cancers grow, like GISTs and mastocytosis. By blocking them, Imatinib can help stop these tumors from growing too.

Yes. Long-term use can cause liver problems, low blood counts, fluid build-up, and muscle or bone pain. In children, it might affect growth. Regular medical tests help catch and manage these problems.

Yes. Grapefruit juice can raise Imatinib levels in the body. Some drugs, like warfarin, statins, or antifungals, can also interact with Imatinib. Always check with your doctor or pharmacist.